Send to

Choose Destination
See comment in PubMed Commons below
Haematologica. 2007 Nov;92(11):1561-4.

Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.

Author information

  • 1Department of Hematology and Oncology, St. Anna Children's Hospital, Kinderspitalgasse 6, A-1090 Vienna, Austria.


Lessons from the analysis of children with TCF3-PBX1 ALL could help to identify treatment components essential for this leukemia subtype. Of 859 children with ALL who were treated in ALL-BFM trials in Austria, 31 (3.6%) had a TCF3-PBX1 ALL. The 5-year event-free survival rate for these 31 patients was 90%+/-5%. Patients with TCF3-PBX1 ALL treated on the ALL-BFM 86 trial had a poorer outcome than patients with TCF3-PBX1 ALL treated on later trials. These data document that contemporary ALL-BFM treatment is highly effective in children with TCF3-PBX1 ALL. Implementation of early dose-intensified remission induction may be an essential treatment component.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center